The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FOLFIRI as second-line (2L) treatment of metastatic gastric cancer (mGC) in clinical practice: Efficacy, safety, and prognostic factors.
Miguel J. Sotelo
No relevant relationships to disclose
Carlos Aguado
No relevant relationships to disclose
Javier Sastre
No relevant relationships to disclose
Beatriz García-Paredes
No relevant relationships to disclose
Aránzazu Manzano
No relevant relationships to disclose
Mónica Granja
No relevant relationships to disclose
Gloria Marquina
No relevant relationships to disclose
Hector R. Callata Carhuapoma
No relevant relationships to disclose
Daniel Alejandro Acosta Eyzaguirre
No relevant relationships to disclose
Jose-Luis Gonzalez-Larriba
No relevant relationships to disclose
Santiago Cabezas
No relevant relationships to disclose
Eduardo Diaz-Rubio
No relevant relationships to disclose